APA (7th ed.) Citation

Sahraian, M. A., Abolfazli, R., Shaygannejad, V., Ashtari, F., Majdinasab, N., Navardi, S., . . . Albooyeh, S. (2024). Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis. Scientific Reports, 14(1), . https://doi.org/10.1038/s41598-024-75745-y

Chicago Style (17th ed.) Citation

Sahraian, Mohammad Ali, et al. "Evaluating Efficacy and Safety of Ocrelizumab Biosimilar (Xacrel) Compared to the Originator (Ocrevus) in Relapsing Multiple Sclerosis." Scientific Reports 14, no. 1 (2024). https://doi.org/10.1038/s41598-024-75745-y.

MLA (9th ed.) Citation

Sahraian, Mohammad Ali, et al. "Evaluating Efficacy and Safety of Ocrelizumab Biosimilar (Xacrel) Compared to the Originator (Ocrevus) in Relapsing Multiple Sclerosis." Scientific Reports, vol. 14, no. 1, 2024, https://doi.org/10.1038/s41598-024-75745-y.